Vimta Labs Limited has revised its Memorandum of Association (MOA) and Articles of Association (AOA).
The revision includes the insertion of Clause No. 7 and Clause No. 8 under the Object Clause of the MOA, as approved by shareholders at the 35th Annual General Meeting held on 6th June 2025.
Clause No. 7 pertains to Contract Research and Development Activities (CDMO) in drug discovery, biotechnology, pharmaceuticals, and related fields.
Clause No. 8 relates to research and development of biologics, biosimilars, peptides, and complex generics, including process and product development for manufacturing and packaging.